Research programme: amphiphile cytokines - Elicio Therapeutics
Latest Information Update: 08 Sep 2023
At a glance
- Originator Elicio Therapeutics
- Class Antineoplastics; Cytokines; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 07 Sep 2023 Early research in Cancer is ongoing in USA
- 28 May 2023 No recent reports of development identified for research development in Cancer in USA
- 04 Apr 2019 Early research in Cancer in USA (unspecified route) (Elicio pipeline, April 2019)